LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.
Espinoza Octavio (Chief Financial Officer) sold 31,641 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.06 ($9.24M total) on 2026-08-12 under a Rule 10b5-1 trading plan.
Haas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.
Over the past 7 days, alphai's AI scored 1 news story mentioning LGND (LIGAND PHARMACEUTICALS INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LGND coverage spans earnings, insider activity and mergers & acquisitions.
In the last 30 days, LGND insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($11.3M). The most active reporter was Haas Jason with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Earnings beat and guidance raise suggest upside, but high debt and reliance on non‑operating gains add risk.
The filing is a direct insider sale by the CFO under a 10b5-1 plan, which can modestly affect sentiment but is not a fundamental change by itself.
An insider open-market sale is disclosed, but the filing provides no new operational or guidance catalyst.
Guidance raise plus capital deployment (convertible notes) and XOMA Royalty scale/diversification are likely to support near-term sentiment, but execution and partner royalty variability remain key risks.
The earnings call summary provides fresh, quantified guidance and acquisition integration expectations that can drive near-term repricing and positioning.
alphai scores every news story that mentions LGND with an AI model for sentiment and relevance, and aggregates insider trades from LIGAND PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.
3 min readEspinoza Octavio (Chief Financial Officer) sold 31,641 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.06 ($9.24M total) on 2026-08-12 under a Rule 10b5-1 trading plan.
1 min readHaas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.
1 min readLigand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.
6 min readLigand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.
7 min readLIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, F
6 min readReardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $288.99 ($284.14–$292.82, $1.44M total) across 10 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readWall Street futures rose Tuesday after major U.S. indices fell Monday. The article lists analyst rating changes and price targets for stocks including Adobe (ADBE) downgraded to Underweight with a $240 target, Salesforce (CRM) cut to Equal Weight with a $185 target, and Microsoft (MSFT) assumed Overweight with a $600 target. It also cites moves for Datadog, Fortinet, Five Below, Gilead, and others.
4 min readXOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.
2 min readLigand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty for $39.00 per share in cash, totaling about $739 million equity value, plus one CVR per share tied to 75% of net litigation proceeds. The deal adds seven commercial products and 100+ development assets, expanding its portfolio to 200+ royalties. Expected EPS accretion: +$0.50 (2026) and +$1.50 (2027).
3 min read
